Research programme: epigenetic cancer therapeutics: Inventiva Pharma

Drug Profile

Research programme: epigenetic cancer therapeutics: Inventiva Pharma

Alternative Names: EHMT2 inhibitors - Inventiva Pharma; Enhancer of zeste homolog 2 inhibitors - Inventiva Pharma; euchromatic histone-lysine N-methyltransferase 2 - Inventiva Pharma; EZH2 inhibitors - Inventiva Pharma; G9a inhibitors - Inventiva Pharma; histone-lysine N-methyltransferase inhibitors - Inventiva Pharma; NSD2 inhibitors - Inventiva Pharma

Latest Information Update: 20 Nov 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Inventiva Pharma
  • Developer Curie Institute; Inventiva Pharma
  • Class
  • Mechanism of Action EZH2 enzyme inhibitors; Histone-lysine N-methyltransferase inhibitors; Immunomodulators; Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Breast cancer; Multiple myeloma; Non-Hodgkin's lymphoma; Ovarian cancer; Respiratory tract disorders; Skin cancer

Most Recent Events

  • 20 Nov 2015 Early research in Breast cancer in France (unspecified route)
  • 20 Nov 2015 Early research in Multiple myeloma in France (unspecified route)
  • 20 Nov 2015 Early research in Non-Hodgkin's lymphoma in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top